SANA BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.5 USD | -1.45% |
|
-6.48% | +83.82% |
Presenter SpeechGeoffrey Meacham (Analysts)So welcome to the first day of the BofA Health Care...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.
Calendar
2024-06-06
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
7.5
USD
Average target price
11.5
USD
Spread / Average Target
+53.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +83.82% | 1.66B | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- SANA Stock
- News Sana Biotechnology, Inc.
- Transcript : Sana Biotechnology, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03
